Phentermine/topiramate - VIVUS

Drug Profile

Phentermine/topiramate - VIVUS

Alternative Names: PHEN/TPM; Phentermine and topiramate extended-release capsules - VIVUS; Phentermine/CR topiramate - VIVUS; Qnexa; Qsiva; Qsymia; Topiramate/phentermine; VI-0521

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator VIVUS
  • Class Amphetamines; Anorectics; Hexoses; Ketoses; Small molecules; Sulfonic acids
  • Mechanism of Action Adrenergic receptor agonists; AMPA receptor antagonists; Carbonic anhydrase inhibitors; Central nervous system stimulants; GABA A receptor agonists; Glutamate agonists; Kainic acid receptor antagonists; Neurotransmitter stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Obesity
  • Phase II Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 21 Jul 2016 The United States District Court for the District of New Jersey issues a claim construction ruling governing patent litigation brought by VIVUS against Teva and Actavis in response to ANDAs filed by both the companies for phenteramine/topiramate
  • 22 Mar 2016 Vivus initiates enrolment in a phase IV trial for Obesity (In adolscents) in USA (NCT02714062)
  • 09 Sep 2015 Phase-II development was compleed for Sleep apnoea and Type-2 diabetes mellitus in obese patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top